The request – published in the US Federal Register earlier this week – covers the production of six Schedule II active pharmaceutical ingredients (APIs), including hydrocodone, amphetamine, methylphenidate and sufentanil.
According to the filing Johnson Matthey “plans to utilize this facility to manufacture small quantities of the listed controlled substances in bulk and to conduct analytical testing in support of the company's primary manufacturing facility in West Deptford, New Jersey.
“The controlled substances manufactured in bulk at this facility will be distributed to the company's customers.”
Publication of the request comes just a few days after the firm said that restructuring of its UK narcotic API business had worked to offset the negative impact that increased competition had had on its business in the country.